FY2020 · ended Dec 31, 2020 · Revenue $257,000 · Filed Mar 30, 2022
Savara Inc (SVRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$101.1 million. As of Jun 30, 2026 it held $173.0 million in cash and investments and $31.2 million in total debt.
Revenue
$257,000
Net income (TTM)
$-45.45M
+32.8% vs year-ago TTM
Operating cash flow (TTM)
$-110.38M
-11.0% vs year-ago TTM
Free cash flow (TTM)
$-110.66M
-11.3% vs year-ago TTM
EPS
$-0.53
-10.4% vs prior year
Dividend per share
None
Shares outstanding
204.66M
+18.6% vs prior year
Net cash
$141.83M
as of Jun 30, 2026
Operating margin
-19182.9%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1160308
- Former names
- Mast Therapeutics, Inc. (until Apr 25, 2017); ADVENTRX PHARMACEUTICALS INC (until Mar 1, 2013); BIOKEYS PHARMACEUTICALS INC (until May 15, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$123.5M | -$103.2M | -$60.0M | -$38.8M | -$41.5M |
| Net income | -$118.8M | -$95.9M | -$54.7M | -$38.1M | -$43.0M |
| Diluted EPS | -$0.53 | -$0.48 | -$0.33 | -$0.25 | — |
| Operating cash flow | -$101.0M | -$89.1M | -$51.1M | -$34.6M | -$40.1M |
| Free cash flow | -$101.1M | -$89.1M | -$51.4M | -$34.6M | -$40.1M |
| Total assets | $253.4M | $212.9M | $177.6M | $139.8M | $176.6M |
| Total liabilities | $50.3M | $41.4M | $37.2M | $32.0M | $32.1M |
| Stockholders' equity | $203.1M | $171.4M | $140.4M | $107.8M | $144.5M |
| Cash and investments | $235.7M | $196.3M | $162.3M | $125.9M | $161.2M |
| Total debt | $30.0M | $26.8M | $26.7M | $26.2M | $25.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 8, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 13, 2026 | Mar 10, 2026 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 1000 Savara Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.